Intranasal application of xenon: Describing the pharmacokinetics in experimental animals and the increased pain tolerance within a placebo-controlled experimental human study

British Journal of Anaesthesia

Volumn 104, Issue 3, 2010, Pages 351-358

  Froeba, G ^a   Georgieff, M ^a   Linder, E M ^a   Fohr, K J ^a   Weigt, H U ^b   Holstrater, T F ^c   Kolle, M A ^a   Adolph, O ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b SLK Kliniken Heilbronn   (Germany)

^c BUNDESWEHRKRANKENHAUS ULM   (Germany)

Author keywords

Anaesthetics gases; Drug delivery; Experimental; Nasal; Pain; Pharmacokinetics; Uptake

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; XENON;

ADULT; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; CLINICAL TRIAL; COLD EXPOSURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; ISCHEMIA; LOW DRUG DOSE; MALE; MECHANICAL STIMULATION; NOCICEPTION; NONHUMAN; NORMAL HUMAN; PAIN THRESHOLD; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWINE;

EID: 77249147458     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aep395     Document Type: Review

References (42)

1. Benrath J, Kempf C, Georgieff M, Sandkühler J. Xenon blocks the induction of synaptic long-term potentiation in pain pathways in the rat spinal cord in vivo. Anesth Analg 2007; 104: 106-111
2. Sandkühler J. Understanding LTP in pain pathways. Mol Pain 2007; 3: 9
3. Adolph O, Kö ster S, Georgieff M, et al. Xenon-induced changes in CNS sensitization to pain. Neuroimage 2010; 49: 720-730
4. Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg 2004; 99: 482-495
5. Bell RF, Dahl JB, Moore RA, Kalso E. Peri-operative ketamine for acute post-operative pain: a quantitative and qualitative systematic review (Cochrane review). Acta Anaesthesiol Scand 2005; 49: 1405-1428
6. Kissin I. Preemptive analgesia at the crossroad. Anesth Analg 2005; 100: 754-756
7. Franks NP, Dickinson R, de Sousa SL, Hall AC, Lieb WR. How does xenon produce anaesthesia? Nature 1998; 396: 324
8. Preckel B, Weber NC, Sanders RD, Maze M, Schlack W. Molecular mechanisms transducing the anesthetic, analgesic, and organ-protective actions of xenon. Anesthesiology 2006; 105: 187-197
9. Salmi E, Laitio RM, Aalto S, et al. Xenon does not affect gamma-aminobutyric acid type A receptor binding in humans. Anesth Analg 2008; 106: 129-134
10. Gruss M, Bushell TJ, Bright DP, et al. Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol 2004; 65: 443-452
11. Bantel C, Maze M, Trapp S. Neuronal preconditioning by inhalational anesthetics: evidence for the role of plasmalemmal adenosine triphosphate-sensitive potassium channels. Anesthesiology 2009; 110: 986-995
12. Dinse A, Föhr KJ, Georgieff M, Beyer C, Bulling A, Weigt HU. Xenon reduces glutamate-, AMPA-, and kainate-induced membrane currents in cortical neurones. Br J Anaesth 2005; 94: 479-485
13. Derwall M, Coburn M, Rex S, et al. Xenon: recent developments and future perspectives. Minerva Anestesiol 2009; 75: 37-45
14. Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004; 56: 3-17
15. Mathias NR, Hussain MA. Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci 2010; 99: 1-20
16. Hussain MA, Aungst BJ, Kapil R, Mousa SA. Intranasal absorption of the platelet glycoprotein IIb/IIIa receptor antagonist, DMP 755, and the effect of anesthesia on nasal bioavailability. J Pharm Sci 1997; 86: 1358-1360
17. Petersen-Felix S, Arendt-Nielsen L. From pain research to pain treatment: the role of human experimental pain models. Best Pract Res Clin Anaesthesiol 2002; 16: 667-680 (Pubitemid 38937108)
18. Petersen-Felix S, Arendt-Nielsen L, Bak P, et al. Analgesic effect in humans of subanaesthetic isoflurane concentrations evaluated by experimentally induced pain. Br J Anaesth 1995; 75: 55-60
19. Petersen-Felix S, Arendt-Nielsen L, Bak P, Fischer M, Zbinden AM. Psychophysical and electrophysiological responses to experimental pain may be influenced by sedation: comparison of the effects of a hypnotic (propofol) and an analgesic (alfentanil). Br J Anaesth 1996; 77: 165-171
20. Yagi M, Mashimo T, Kawaguchi T, Yoshiya I. Analgesic and hypnotic effects of subanaesthetic concentrations of xenon in human volunteers: comparison with nitrous oxide. Br J Anaesth 1995; 74: 670-673
21. Lemmens HJ, Bovill JG, Hennis PJ, Gladines MP, Burm AG. Alcohol consumption alters the pharmacodynamics of alfentanil. Anesthesiology 1989; 71: 669-674
22. Froeba G, Marx T, Pazhur J, et al. Xenon does not trigger malignant hyperthermia in susceptible swine. Anesthesiology 1999; 91: 1047-1052
23. Nalos M, Wachter U, Pittner A, et al. Arterial and mixed venous xenon blood concentrations in pigs during wash-in of inhalational anaesthesia. Br J Anaesth 2001; 87: 497-498
24. Wenzel V, Linder KH, Augenstein S, Prengel AW, Strohmenger HU. Vasopressin combined with epinephrine decreases cerebral perfusion compared with vasopressin alone during cardiopulmonary resuscitation in pigs. Stroke 1998; 29: 1462-1467
25. Currie SR, Wilson KG, Gauthier ST. Caffeine and chronic low back pain. Clin J Pain 1995; 11: 214-219
26. Luginbuhl M, Schnider TW, Petersen-Felix S, Arendt-Nielsen L, Zbinden AM. Comparison of five experimental pain tests to measure analgesic effects of alfentanil. Anesthesiology 2001; 95: 22-29
27. Arendt-Nielsen L, Petersen-Felix S, Fischer M, et al. The effect of N-methyl-D-aspartate antagonist (ketamine) on single and repeated nociceptive stimuli: a placebo-controlled experimental human study. Anesth Analg 1995; 81: 63-68
28. Petersen-Felix S, Luginbuhl M, Schnider TW, et al. Comparison of the analgesic potency of xenon and nitrous oxide in humans evaluated by experimental pain. Br J Anaesth 1998; 81: 742-747
29. Grön G, Bittner D, Schmitz B, Wunderlich AP, Riepe MW. Subjective memory complaints: objective neural markers in patients with Alzheimer's disease and major depressive disorder. Ann Neurol 2002; 51: 491-498
30. Zimmermann P, Fimm A. Testbatterie zur Aufmerksamkeitsprüfung. TAP (V. 1.02). Würselen: Psytest, 1994
31. Posner MI. Measuring alertness. Ann N Y Acad Sci 2008; 1129: 193-199
32. Coburn M, Kunitz O, Apfel CC, et al. Incidence of postoperative nausea and emetic episodes after xenon anaesthesia compared with propofol-based anaesthesia. Br J Anaesth 2008; 100: 787-791
33. Arendt-Nielsen L, Nielsen J, Petersen-Felix S, Schnider TW, Zbinden AM. Effect of racemic mixture and the (S+)-isomer of ketamine on temporal and spatial summation of pain. Br J Anaesth 1996; 77: 625-631
34. Sonner JM, Antognini JF, Dutton RC, et al. Inhaled anesthetics and immobility: mechanisms, mysteries, and minimum alveolar anesthetic concentration. Anesth Analg 2003; 97: 718-740
35. Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000; 85: 483-491
36. Maurset A, Skoglund LA, Hustveit O, Oye I. Comparison of ketamine and pethidine in experimental and postoperative pain. Pain 1989; 36: 37-41
37. Segerdahl M, Ekblom A, Sollevi A. The influence of adenosine, ketamine, and morphine on experimentally induced ischemic pain in healthy volunteers. Anesth Analg 1994; 79: 787-791
38. Weigt HU, Georgieff M, Beyer C, Wachter U, Föhr KJ. Xenon incorporated in a lipid emulsion inhibits NMDA receptor channels. Acta Anaesthesiol Scand 2003; 47: 1119-1124
39. Lachmann B, Armbruster S, Schairer W, et al. Safety and efficacy of xenon in routine use as an inhalational anaesthetic. Lancet 1990; 335: 1413-1415
40. Danbolt NC. Glutamate uptake. Prog Neurobiol 2001; 65: 1-105
41. Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 2000; 130: 1007S-1015S
42. Maeng S, Zarate CA, Jr. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 2007; 9: 467-474